Although clinical trials of molecular therapies targeting critical biomarkers (mTOR, epidermal
growth factor receptor/epidermal growth factor receptor 2, and vascular endothelial growth …

Molecular targets and targeted therapeutics in endometrial c... : Current Opinion in Oncology
Molecular targets and targeted therapeutics in endometrial cancer : Current Opinion in …

With a lifetime risk among women of 2–3%, endometrial cancer is the most common pelvic
gynecologic malignancy in industrialized countries. Approximately 75% of cases are …

Endometrial cancer is the most prevalent gynecologic cancer in the United States. Over the
last 10 years, death rates from endometrial cancer have been rising about 1.4% per year …

Management of endometrial cancer, an adenocarcinoma of the endometrium which
occupies most uterine corpus neoplasms, including uterine sarcomas, has been more …

Endometrial cancer (EC) has a high epidemiological impact with incidence and mortality
rising worldwide. In recent years, the integration of the pathologic and molecular …

Early stage endometrial cancer is generally curable. However, progress in the treatment of
advanced and recurrent endometrial cancer has been limited. This has led to a shift from the …

Hormonal therapy and chemotherapy play a major role in the management of advanced or
recurrent endometrial cancer. Progesterone therapy obtains overall response rates ranging …

The incidence and mortality rates from endometrial cancer are increasing. There have been
no new drugs approved for the treatment of endometrial cancer in decades. The National …

The treatment for endometrial cancer is rapidly evolving with the development of molecular
analysis and novel strategies. Surgical resection, cytotoxic chemotherapy, endocrine or …